comparemela.com

Latest Breaking News On - Direct event passcode - Page 20 : comparemela.com

Geron Corporation Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

Share: Conference Call Scheduled for 4:30 p.m. ET today Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reported financial results for the fourth quarter and year ended December 31, 2020. The Company ended fiscal year 2020 with $260 million in cash and marketable securities, which is expected to fund operations until the end of 2022. Geron s vision is to be recognized as a leader in the treatment of hematologic malignancies by changing the course of these diseases and thereby improving and extending the lives of patients, said John A. Scarlett, M.D., Chairman and Chief Executive Officer. In 2020, we made important progress toward realizing that vision through two ongoing Phase 3 clinical trials, presentation of new data and analyses providing strong evidence of imetelstat s disease-modifying potential that differentiates imetelstat from

Phoenix New Media to Announce Fourth Quarter and Fiscal Year 2020 Financial Results on Monday, March 15, 2021

Qutoutiao Inc to Report Fourth Quarter 2020 Results on Thursday, March 4, 2021

EVS Broadcast Equipment reports 2020 results

EVS Broadcast Equipment reports 2020 results Regulated information - Press release annual results EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports 2020 results Delivering profitability despite the impact of the pandemic, prepared to grow revenues and emerge stronger in 2021 thanks to a strong order book FY20 performance Operating expense increasing only 1.9% YoY despite the Axon acquisition on May 1 st 2020 Net profit of EUR 7.2 million (-63.4% compared to FY19 mainly due to lower revenue levels) Order intake 2020: -3% YoY (excl Big Event Rentals and including Axon), supported by a strong order intake in 4Q 2020.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.